WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 530208
Description: Becampanel, also known as AMP-397, is an AMPA receptor antagonist potentially for the treatment of epilepsy. Becampanel acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM). It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.
MedKoo Cat#: 530208
Chemical Formula: C10H11N4O7P
Exact Mass: 330.0365
Molecular Weight: 330.1928
Elemental Analysis: C, 36.38; H, 3.36; N, 16.97; O, 33.92; P, 9.38
Synonym: AMP-397; AMP-397A; AMP 397; AMP 397A; AMP397; AMP397A; Becampanel.
IUPAC/Chemical Name: ((((7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)methyl)amino)methyl)phosphonic acid
InChi Key: ABFMMCZFKUIJGQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)
SMILES Code: O=C1C(NC2=C(C(CNCP(O)(O)=O)=CC([N+]([O-])=O)=C2)N1)=O
1: Jahnke W, Bold G, Marzinzik AL, Ofner S, Pellé X, Cotesta S, Bourgier E, Lehmann S, Henry C, Hemmig R, Stauffer F, Hartwieg JC, Green JR, Rondeau JM. A General Strategy for Targeting Drugs to Bone. Angew Chem Int Ed Engl. 2015 Nov 23;54(48):14575-9. doi: 10.1002/anie.201507064. PubMed PMID: 26457482.
2: Suter W, Hartmann A, Poetter F, Sagelsdorff P, Hoffmann P, Martus HJ. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. Mutat Res. 2002 Jul 25;518(2):181-94. PubMed PMID: 12113769.